ConductScience.org, home

Paper9510340

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.

Iversen P and 9 others. Urology, 1998. Cited by 119 papers, by iCite.

Cite this record

ConductScience Library. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Papers, record 9510340. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9510340

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
PubMed
Journal
Urology
PubMed
Year
1998
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
119
iCite
Relative citation ratio, by iCite
3.79
iCite
Revised in PubMed
2019-07-14
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Iversen PP
2Tyrrell CJC J
3Kaisary AVA V
4Anderson JBJ B
5Baert LL
6Tammela TT
7Chamberlain MM
8Carroll KK
9Gotting-Smith KK
10Blackledge GRG R

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Androgen AntagonistsMajor topic
AnilidesMajor topic
Antineoplastic Agents, HormonalMajor topic
CastrationMajor topic
GoserelinMajor topic
Prostatic NeoplasmsMajor topic
Aged
Aged, 80 and over
Disease Progression
Double-Blind Method
Follow-Up Studies
Humans
Male
Middle Aged
Nitriles
Quality of Life
Survival Rate
Time Factors
Tosyl Compounds

Source PubMed

Download CSV of topics

Cited by33

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 119 citations.

PMIDTitleJournalYearIn PapersSource
40752653Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy.Int J Radiat Oncol Biol Phys2025https://conductscience.org/library/papers/40752653PubMed
36347548How can we best manage biochemical failure after radical prostatectomy?Investig Clin Urol2022https://conductscience.org/library/papers/36347548PubMed
33402834A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research.Onco Targets Ther2020https://conductscience.org/library/papers/33402834PubMed
28653121[Radiation with additional antiandrogen therapy in recurrent prostate cancer].Strahlenther Onkol2017https://conductscience.org/library/papers/28653121PubMed
28646463Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging.Eur J Nucl Med Mol Imaging2017https://conductscience.org/library/papers/28646463PubMed
28146658Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.N Engl J Med2017https://conductscience.org/library/papers/28146658PubMed
27141178Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Urol Ann2016https://conductscience.org/library/papers/27141178PubMed
26024831A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.Horm Cancer2015https://conductscience.org/library/papers/26024831PubMed
25829707Can Subepididymal Orchiectomy Re-emerge as the Treatment of Choice in Patients with Advanced Prostatic Carcinoma?Indian J Surg2015https://conductscience.org/library/papers/25829707PubMed
25677235Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.Curr Urol Rep2015https://conductscience.org/library/papers/25677235PubMed
25371601Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Urol Ann2014https://conductscience.org/library/papers/25371601PubMed
24979481Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.Cochrane Database Syst Rev2014https://conductscience.org/library/papers/24979481PubMed
24868335Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer.Korean J Urol2014https://conductscience.org/library/papers/24868335PubMed
24744780Quality of Life and Sexual Health in the Aging of PCa Survivors.Int J Endocrinol2014https://conductscience.org/library/papers/24744780PubMed
21789114Risk stratification in the hormonal treatment of patients with prostate cancer.Ther Adv Med Oncol2009https://conductscience.org/library/papers/21789114PubMed
21673847Saudi Oncology Society clinical management guidelines for prostate cancer.Urol Ann2011https://conductscience.org/library/papers/21673847PubMed
20091248The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis.J Cancer Surviv2010https://conductscience.org/library/papers/20091248PubMed
19290019Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes.Prostate Cancer Prostatic Dis2009https://conductscience.org/library/papers/19290019PubMed
18273599[Androgen deprivation for advanced prostate cancer].Urologe A2008https://conductscience.org/library/papers/18273599PubMed
17971600Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.J Clin Oncol2007https://conductscience.org/library/papers/17971600PubMed

See all 33 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9510340

GET https://conductscience.org/api/papers/v1/9510340/cited_by?page=2